Login to Your Account



In the clinic


Tuesday, June 10, 2014
Quest Pharmatech Inc., of Edmonton, Alberta, reported that patient enrollment has been completed in the company's phase IIb trial of its lead immunotherapy product candidate, oregovomab, to treat ovarian cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription